- MENU
- HOME
- SEARCH
- WORLD
- MAIN
- AFRICA
- ASIA
- BALKANS
- EUROPE
- LATIN AMERICA
- MIDDLE EAST
- United Kingdom
- United States
- Argentina
- Australia
- Austria
- Benelux
- Brazil
- Canada
- China
- France
- Germany
- Greece
- Hungary
- India
- Indonesia
- Ireland
- Israel
- Italy
- Japan
- Korea
- Mexico
- New Zealand
- Pakistan
- Philippines
- Poland
- Russia
- South Africa
- Spain
- Taiwan
- Turkey
- USA
- BUSINESS
- WEALTH
- STOCKS
- TECH
- HEALTH
- LIFESTYLE
- ENTERTAINMENT
- SPORTS
- RSS
- Investing
By Andrew Leckey
The complex prescription for successful healthcare investing usually includes the careful consideration of drug pipelines, current-product sales, patent expirations, potential mergers and stock dividends.
Add to that list in 2010 an untested ingredient called healthcare reform.
"Institutional investors don't want to see big headlines about the healthcare industry that they weren't able to predict," said Les Funtleyder, health care strategist for
If you're in any way optimistic that the outcome of healthcare reform won't be all that bad for drug companies, the current fears mean that healthcare stock prices will never be more reasonable than they are now. Prices are depressed and the dividends solid.
"Once we know what the reform will look like in detail we can then move forward," believes Linda Bannister, healthcare analyst for Edward Jones in St. Louis. "Managed care is the most at risk from healthcare reform, and then the risk declines from there."
Beyond the potential negatives of reform on drug stocks there may be some long-term positives.
"If 30 million people who didn't have health insurance were to have it, imagine what that does for a pharmaceutical company," said James Molloy, pharmaceutical analyst for
While awaiting a clear prognosis on reform, investors must fall back on traditional considerations that tend to favor big pharma that keeps growing bigger.
The other Molloy favorite is "My biggest consideration is whether the good news or bad news is factored into the stock price," explained Molloy. "I also ask whether its primary drug has to be a $1 billion drug for the company's stock price to go higher." Mergers can come fast and furious among drug companies, but is an unpredictable trend that none of the experts expect will take place soon. "Pharma has been a consolidating industry ever since it was an industry," said Funtleyder, noting that patent expirations and slowing sales drove the most recent mergers and innovation may someday drive the next go-around. "Consolidation happens in waves and last year was a pretty big wave, so we think there will be a break for a couple of years before we see the next wave of consolidation." Other Bannister choices include "If a company like Lilly is unable to execute its pipeline, then at some point it is going to have to make a sizeable acquisition or it will potentially be acquired," concluded Bannister, who considers investment in Lilly a three- to five-year story. "Yet most of these companies' strategies are licensing deals or small 'tuck-in' acquisitions, so I'm not betting on a new wave of industry consolidation." © Andrew Leckey
CAREERS |
INVESTING |
PERSONAL FINANCE |
REAL ESTATE
Investing - Healthcare Reform Could Have Positive and Negative Effects on Drug Stocks